OBI Share Price Performance
UK£0.10
0.02 (32.26%)
81.4% undervalued intrinsic discount
UK£0.55
Fair Value
Price UK£0.10
AnalystConsensusTarget UK£0.55
Fair ValueUK£0.55
Share Pricen/a
Ondine Biomedical Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
OBI Community Narratives
AN
Fair Value UK£0.55 81.4% undervalued intrinsic discount
Mölnlycke Deal And US Trials Will Open International Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Mölnlycke Deal And US Trials Will Open International Markets
Key Takeaways A major partnership is expected to enhance Steriwave's market entry and international sales, boosting revenue and growth opportunities significantly. Investments in automation and funding aim to support long-term scaling and sustainable growth, improving operational efficiencies and cost management.Read more
23
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
UK£0.55
81.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
158.03% p.a.
Profit Margin
10.1%
Future PE
188.34x
Price in 2028
UK£0.41
Trending Discussion
Recently Updated Narratives
AN
Mölnlycke Deal And US Trials Will Open International Markets
Fair Value: UK£0.55 81.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ondine Biomedical Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.054
- 65.77%
- -1,084.66%
- 0%
About OBI
- Founded
- 1996
- Employees
- n/a
- CEO
- WebsiteView website
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as catheter-associated urinary tract infection. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.
